Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetics Generation Advancement (ROCO:4160) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Genetics Generation Advancement Forward PE Ratio Related Terms
Genetics Generation Advancement Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement Forward PE Ratio Chart
Genetics Generation Advancement Annual Data
Trend
Forward PE Ratio
Genetics Generation Advancement Quarterly Data
Forward PE Ratio
ROCO:4160 vs TMO, DHR, IDXX: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, Genetics Generation Advancement's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's Forward PE Ratio falls into.
Genetics Generation Advancement Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Genetics Generation Advancement (ROCO:4160) has a Forward PE Ratio of 0.00 as of Aug. 15, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Genetics Generation Advancement and its competitors. According to the industry distribution chart, Genetics Generation Advancement ranks #999999 out of 87 companies in the Medical Diagnostics & Research industry.
Is Genetics Generation Advancement's Forward PE Ratio too high?
Genetics Generation Advancement's current Forward PE Ratio is 0.00. Based on the distribution chart, Genetics Generation Advancement ranks #999999 out of 87 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Genetics Generation Advancement has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's Forward PE Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #999999 out of 87 companies for Forward PE Ratio. This places Genetics Generation Advancement in the lower half of its industry. The industry median Forward PE Ratio is 23.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 23.72, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Genetics Generation Advancement and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 23.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetics Generation Advancement's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$53.64, compared to a current price of NT$39.80 — trading 25.8% below its estimated fair value. The current Forward PE Ratio is 0.00. Genetics Generation Advancement's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current Forward PE Ratio is 0.00 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$39.80 is trading 25.8% below its estimated GF Value™ of NT$53.64.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
Forward PE Ratio: 0.00
GF Value™: NT$53.64 vs. price of NT$39.80 (25.8% below fair value)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
69GF Score
Get the complete analysis for ROCO:4160
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
